CMS NTAP Granted for Reflow Medical Spur Peripheral Retrievable Stent System

September 2, 2026—Reflow Medical, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for the company’s Spur peripheral retrievable stent system, providing additional reimbursement for eligible fee-for-service Medicare inpatient cases beginning October 1, 2026.

The company stated that under the fiscal year 2027 NTAP program, qualifying inpatient cases involving the Spur stent system are eligible for an incremental payment up to $2,596.75, in addition to the applicable Medicare severity diagnosis-related group payment. The NTAP is available for a period of up to 2 years.

Actual payment is determined on a case-by-case basis in accordance with the applicable CMS and NTAP methodology used, advised Reflow Medical.

Isa Rizk, CEO and Cofounder of Reflow Medical, commented in the press release, “This is an important milestone for Spur and for our continued efforts to support physicians treating patients with infrapopliteal arterial disease, a population with significant unmet clinical needs.”

Additional information about Spur reimbursement, coding, NTAP, and payment methodology is available on the company’s website.

In May 2025, Reflow announced that the FDA granted de novo clearance for the Spur system for the treatment of de novo or restenotic lesions after predilatation in patients with infrapopliteal arterial disease. The Spur system had previously gained FDA Breakthrough Device designation.

According to Reflow Medical, the Spur system is intended as an adjunct to percutaneous transluminal angioplasty to dilate stenoses in infrapopliteal arteries ranging in diameter from 2.5 to 4.5 mm. The Spur stent provides temporary mechanical scaffolding and is retrieved after treatment, leaving no permanent implant behind, noted the company.